On February 21, 2017, the US Patent Office granted BioArctic a patent (Patent No. US 9,573,994 B2) for the company’s antibody BAN2401 Backup for Alzheimer’s disease.
With this patent and previous patents BioArctic has secured IP rights for the company’s unique disease modifying immunotherapeutic approach for Alzheimer’s disease. The antibodies are selectively targeting and reducing amyloid-beta neurotoxic protofibrils.
BioArctic’s lead drug candidate is a humanized monoclonal antibody, BAN2401, targeting and reducing the toxic oligomers/protofibrils believed to cause Alzheimer’s disease. BAN2401 is in Phase 2b clinical trial in early Alzheimer patients in the US, Canada, EU and Asia.
Since 2005 the company has partnered with Eisai for research in Alzheimer’s disease. BioArctic also engages in in-house research and development concerning Alzheimer’s disease.
For more information, please contact:
Gunilla Osswald, CEO, BioArctic AB
Pär Gellerfors, Senior Vice President Business Strategy, Founder, BioArctic AB
Telephone +46 (0)8 695 6930